SuperGen, Inc. Presents Preclinical Data On Selected Lead Kinase Compounds And DNA Methylation Inhibitor At EORTC

PRAGUE, Czech Republic, Nov. 10 /PRNewswire-FirstCall/ -- SuperGen Inc. today announced the presentation of data on two lead compounds and a promising lead molecule from its DNA methylation inhibitor program during the scientific sessions at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

SuperGen scientists and collaborators from the University of Arizona and the USC/Norris Comprehensive Cancer Center presented two posters that pertained to selected lead kinase inhibitor compound MP-470, a DNA repair suppressor and kinase inhibitor, and MP-371, a multi-targeted tyrosine kinase inhibitor. In addition, Dr. Peter Jones, director of the USC Norris Comprehensive Cancer Center, delivered a plenary presentation that highlighted the activity of a lead molecule from the company's DNA methylation inhibitor program that is a potent DNA hypomethylating agent and the first compound to demonstrate improved activity and stability over decitabine.

"SuperGen is very proud to be presenting data at EORTC that demonstrates the rapid clinical progress we've made with several novel lead compounds," commented Dr. James S. Manuso, SuperGen's Chairman, President and Chief Executive Officer. "We are on track to file the IND and initiate Phase I clinical testing with MP-470 in the first half of 2007, and our second product candidate, MP-529, a potent aurora kinase inhibitor compound that we presented data on yesterday, should move into the clinic shortly after MP-470 in the coming year. Our DNA methylation inhibitor program has also made exciting progress, producing the first compound to demonstrate improved activity and stability over decitabine."

Poster No. 532 c-Met inhibition radiosensitizes melanoma by inhibiting double strand DNA repair

c-Met is a pro survival gene that provides resistance to various cytotoxic therapies, including radiation, and is implicated in various human malignancies. Dr. James Welsh's studies demonstrated exciting activity of MP-470, a c-Met inhibitor, when used alone and combined with radiation in both Glioblastoma and Melanoma models.

Poster No. 622 Discovery and characterization of a novel multi-targeted tyrosine kinase inhibitor with activity against c-Ret, PDGFR, c-Kit and c-Src

Data show that lead compound MP371, a selective multi-targeted tyrosine kinase inhibitor, exhibits good inhibitory activity against c-Ret, PDGFR, c-Kit, and c-Src with IC50 concentrations in the 50-150 nm range. This potent inhibitor possesses ADME properties that suggest good "druggability" and is active against a variety of tumor types, including medullary thyroid carcinoma, gastrointestinal stromal tumors and pancreatic adenocarcinoma, three difficult-to-treat diseases.

Plenary Session No. 9: Discovering Novel Targets and Therapeutics for Cancer The importance of epigenetics in drug discovery and development.

Dr. Peter Jones highlighted the activity of a lead molecule from SuperGen's development program that is a potent DNA hypomethylating agent. This compound is the first to demonstrate improved stability and activity over decitabine by delivering 5-aza-2' -deoxycytidine in a bi-nucleotide form with Guanine. This bi-nucleotide helps increase stability of decitabine while maintaining potent DNA hypomethylating activity.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com .

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding SuperGen's estimate of its potential tax liability. Important factors that could cause the potential tax liability to be higher or lower include, but are not limited to, the final determination of the potential liability which is currently being assessed. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein, (212) 845-4271 S.V.P., Corporate Communications & (Investors) Business Development sharon.weinstein@eurorscg.com (925) 560-0100 x111 tenns@supergen.com Tracey Milani, (858) 546-4811 (Media) tracey.milani@eurorscg.com

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications &BusinessDevelopment of SuperGen Inc., +1-925-560-0100 x111, tenns@supergen.com; orInvestors, Sharon Weinstein of Noonan Russo for SuperGen Inc.,+1-212-845-4271, sharon.weinstein@eurorscg.com, or Media, Tracey Milani,+1-858-546-4811, tracey.milani@eurorscg.com

Web site: http://www.supergen.com/